Genentech, Inc.

Boehringer Ingelheim International Gmbh

New Biology, Inc.

Justin M Scheer

Philip E Hass

Richard L Vandlen

Wenjun Ouyang

Eric Gary Stefanich

Xiaoting Wang

Robert F Kelley

Pankaj Gupta

Devin Tesar

Whitney Shatz

Rajkumar Ganesan

Menno Van Lookeren Campagne

Paul Adam

Christoph Spiess

Priyanka Gupta

Michael Dziegelewski

Philip Nicholas Gorman

Vladimir H Voynov

Amy Lim

Josefine Persson

Ganesh A Kolumam

Glen Giese

Ambrose Williams

Barbara Scheer

Paul J Carter

Isidro Hotzel

Teemu T Junttila

Susanne Hipp

Ji Li

Diego Ellerman

Nicholas Van Bruggen

Danielle Dicara

Wyne Pun Lee

Jed Ross

Leo Thomas

Daniel G Yansura

Remko Alexander Bakker

Sarah Low

Fei Han

Sandeep Kumar

Peter Michael Benz

Domingos Ng

J Michael Elliott

Michelle Dion

Marcio Lasaro

Eric Borges

Holger Fuchs

Abdallah Souabni

Inigo Tirapu

Joseph Ronald Tumang

Daniel Christopher Rowe

The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Multi-specific binding proteins for cancer treatment

This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.

Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer

This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.

Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases

The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule. The methods modulate parameters to improve assembly of the heteromultimeric proteins at higher yield and efficiency than otherwise possible. Also described are compositions comprising a hinge-containing polypeptide, such as a half-antibody.

Assembly of bispecific antibodies

The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

IL-22 Fc fusion proteins

The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.

Humanized and affinity matured antibodies to FcRH5 and methods of use

Methods of treating acute pancreatitis using IL-22 fc fusion proteins

Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins

Methods for treating metabolic syndrome using IL-22 Fc fusion proteins

The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.

Anti-factor D antibody variant conjugates and uses thereof

Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.

Production of heteromultimeric proteins using mammalian cells

Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.

Fc variants and methods for their production

Growing community of inventors

Ridgefield, CT, United States of America

Justin M Scheer